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Tablet quality control testsAbstract The use of potassium iodide (KI) as a protective agent against accidental radioactive
exposure is well established. In this study, we aimed to prepare a KI tablet formulation using a
direct compression method. We utilized Design of Experiment (DoE)/mixture design to deﬁne
the best formulation with predetermined physical qualities as to its dissolution, hardness, assay,
disintegration, and angle of repose. Based on the results from the DoE, the formulation had the
following components (%w/w): Avicel 48.70%, silicon dioxide 0.27%, stearic acid (1.00%), magne-
sium stearate 2.45%, and dicalcium phosphate 18.69%, in addition to potassium iodide 28.89%
(130 mg/tablet). This formulation was scaled-up using two tablet presses, a single-punch press
and a rotary mini tablet press. The ﬁnal scaled-up formulation was subjected to a variety of quality
control tests, including photo-stability testing. The results indicate that potassium iodide tablets
prepared by a rotary mini tablet press had good pharmaceutical characteristics and a shelf-life of
25 days when stored at room temperature protected from light.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
As a trace element iodine is essential for the proper functioning
of the thyroid gland as well as for other bodily normal
metabolic functions. Goiter development is often associated
with iodine deﬁciency. (Hendler, 2001) The thyroid glandpreferentially absorbs iodine in its reduced form iodide. Inside
the thyroid gland, iodine gets converted to triiodothyronine
(T3) and thyroxine (T4) which are released into the systemic
circulation for other bodily functions (Hendler, 2001; http://
books.nap.edu/openbook.php?record_id=10868&page=
R1). Iodide supplements, such as potassium iodide (KI), are
available as iodide replenishing agents. Potassium iodide in
particular may be used as an expectorant medication, to
overcome a hyperactive thyroid, and systemically as an anti-
fungal agent (Hendler, 2001; http://en.wikipedia.org/wiki/
Potassium_iodide; http://www.drugs.com/mtm/potassium-
iodide.html). Perhaps one of the main uses of KI is as a
protectant against harmful radiation effects such as the one
released in the air after a radioactive nuclear plant accident
(FDA, 2002). Under these situations, radioactive iodine may
96 A. Al-Achi, B. Patelbe released to the environment surrounding the nuclear plant
facility, and people living in the vicinity of the plant may be
subject to dangerous radioactive exposure. The presence of
radioactive iodine (131I) in the thyroid gland may lead to the
development of thyroid cancer. If taken during such
emergencies, KI can saturate the thyroid tissues with iodine,
preventing the accumulation of the radioactive form in these
tissues (Hendler, 2001; http://books.nap.edu/openbook.
php?record_id=10868&page= R1; FDA, 2002). Nuclear
plant accidents, such as the ones occurred in April 1986 in
Chernobyl (Ukraine) and more recently at the Fukushima
Daiichi facility in Japan (2011), have prompted the authorities
to consider the use of KI as a protective agent. For example,
during the Chernobyl nuclear accident in the former Soviet
Union, the authorities there distributed approximately 18 mil-
lion doses of KI to the public following the incident, and stud-
ies since then revealed the absence of thyroid cancer in people
who were treated with KI (http://en.wikipedia.org/wiki/
Potassium_iodide; FDA, 2001, 2002).
In the Federal Register of December 15, 1978, the US Food
and Drug Administration (FDA) declared that KI is a safe and
effective measure to be taken during nuclear disasters. And, in
the Federal Register of June 29, 1982, the FDA afﬁrmed its
earlier recommendation of administrating KI to the general
public during nuclear incidents. In the United States, the
FDA has approved several KI products since 2005 (Iosat,
ThyroSafe, and ThyroShield). The FDA recommended a daily
dose of 130 mg for adults and half that amount for anyone
who is 18 years old or younger (FDA, 2001, 2003) To be effec-
tive, the dose should be given shortly before, immediately, or
within four hours after the radio-iodine exposure. The FDA
emphasizes the fact that administering KI is only one measure
to be taken among others (seeking shelter, evacuation, etc.)
during such emergencies (FDA, 2001, 2002, 2004).
The preparation of KI tablets may be achieved by a direct
compression method. In this method, a dry blend of powders
composed of active ingredients and ﬁllers is prepared and then
compressed as is on a tablet press without any added
manipulations. Although this method is limited to only a few
drugs, it is in particular suitable for potassium salts, such as
KI (Shangraw, 1989; Armstrong, 2007; Shrewsbury, 2008).
This method suffers from some disadvantages such as theTable 1 Mixture design table.
Run Avicel Silicon
dioxide
Stearic
acid
Magnesium
stearate
Dicalcium
phosphate
1 0.5 0.005 0.03 0.05 0.415
2 0.5 0.005 0.01 0.0025 0.4825
3 0.2 0.005 0.01 0.05 0.735
4 0.5 0.001 0.01 0.0025 0.4865
5 0.2 0.001 0.01 0.0025 0.7865
6 0.5 0.001 0.03 0.05 0.419
7 0.2 0.005 0.03 0.0025 0.7625
8 0.2 0.001 0.03 0.0025 0.7665
9 0.5 0.005 0.03 0.05 0.415
10 0.2 0.005 0.01 0.05 0.735
11 0.5 0.005 0.01 0.0025 0.4825
12 0.5 0.001 0.01 0.05 0.439
13 0.5 0.001 0.03 0.0025 0.4665
14 0.2 0.001 0.01 0.05 0.739
15 0.2 0.001 0.03 0.05 0.719build-up of static charge due to the dry nature of the powders
being used and stratiﬁcation within the granulation due to dif-
ferences in the particle size and bulk density of the ingredients
within a blend (Banker, 1991). However, several advantages to
the method are recognized such as the absence of moisture and
heat, less processing time, and fewer manufacturing
equipment, among others (Shangraw, 1989; Armstrong,
2007; Banker, 1991).
The objective of this study was to formulate a tablet dosage
form for potassium iodide using a direct compression method
with the ﬁnal aim of scaling-up the formulation to a ﬁnished
dosage form.
2. Materials and methods
2.1. Materials
Potassium iodide was obtained from Acros Organics (Lot No.
A0270423, NJ, USA). The other ingredients were purchased
from their speciﬁed companies as follows: Dicalcium phos-
phate (JRS Pharma, Lot No. 7050X, Rosenberg, Germany),
Avicel (FMC Corporation, Lot No. M218C, Philadelphia,
PA), silicon dioxide (Cabot Corporation, Lot No. 1E128,
Tuscola, IL), stearic acid (Fisher Scientiﬁc, Lot No. 880352,
Fairlawn, NJ), and magnesium stearate (Spectrum Chemicals,
Lot No. UJ0399, New Brunswick, NJ).
2.2. Methods
2.2.1. Design of experiment (DoE)/mixture design
We conducted a DoE/mixture design with 15 runs (Table 1).
The design speciﬁcations are summarized in Table 2. The pur-
pose of this design was to ﬁnd the best composition that met
the requirement in Table 2 (Section 2.A.). JMP Statistical
Discovery Software (V. 10.0) (SAS Institute, Cary, North
Carolina)/Design of Experiment facility was used in construct-
ing the design and analyzing the data. The lower and upper
limits of the ingredients listed in Table 2 (Section 2.B.) were
determined from a reference handbook for pharmaceutical
excipients (Rowe et al., 2006). Tests speciﬁcations followed
USP guidelines as outlined in the subsequent sections.Dissolution Hardness
(kilopond)
Assay
(mg)
Disintegration
(min)
Angle of
repose ()
. . . . .
. . . . .
. . . . .
. . . . .
. . . . .
. . . . .
. . . . .
. . . . .
. . . . .
. . . . .
. . . . .
. . . . .
. . . . .
. . . . .
. . . . .
Table 2 Mixture design speciﬁcations.
Response name Goal Lower limit Upper limit
2.A. Response name, goal and limits for mixture design
Dissolution Maximize 0 0.75
Hardness Match target 6 12
Assay Match target 122.2 137.8
Disintegration Match target 0 5
Angle of repose Minimize . .
Name Role Changes Values
2.B. Factor name, role, changes and values for mixture design
Avicel Mixture Easy 0.2 0.5
Silicon Dioxide Mixture Easy 0.001 0.005
Stearic Acid Mixture Easy 0.01 0.03
Magnesium Stearate Mixture Easy 0.0025 0.05
Dicalcium Phosphate Mixture Easy 0 0.7865
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The ingredients were weighed as per Design of Experiment
(DoE) runs. All the ingredients except magnesium stearate
and stearic acid were transferred to porcelain mortar-pestle.
Powders were mixed by hand for 5 minutes. Then, magnesium
stearate and stearic acid were added to the mortar and mixed
for 2 min. After that, amaranth dye (0.1% w/w) was added to
mortar-pestle. The powders were mixed till homogenous blend
of powder was obtained. (Homogenous distribution of ama-
ranth throughout the powder mixture indicated blend
uniformity).
2.2.3. Tablet manufacturing
From the powder blend, quantity equal to 450 mg was weighed
on weighing balance (Ohaus Corporation, Model No. PA153).
The weighed quantity was transferred manually into the die
(11 mm) of the Carver press (Carver Inc., Model No. 3912).
Using the Carver press, the powder blend was compressed into
tablets (80 tablets per run were prepared.) Compression force
equal to 2000 pounds (i.e., @ 0.9 metric tons @ 600 psi) was
used to compress the powder into tablets.
2.2.4. Dissolution test <USP 32: 711>
The following speciﬁcations were adopted for this test: The
medium was DI water (900 mL), a Type II Apparatus,
50 rpm speed, and a run time of 15 minutes. The stated volume
of the dissolution medium (±1%) was placed in the vessel of
the apparatus. The dissolution medium was equilibrated to
37 ± 0.5 C. The dosage unit was placed and allowed to sink
to the bottom of the vessel. The apparatus was operated imme-
diately at 50 RPM for 15 minutes. After the test was carried
out, a specimen was withdrawn from a zone midway between
the surface of the dissolution medium and the top of the rotat-
ing blade. The withdrawn specimen was ﬁltered using a 0.2 lm
syringe ﬁlter. Analysis of the specimen was performed as direc-
ted in the monograph using a suitable assay method. The
amount of KI dissolved was determined from UV absorbance
at the wavelength of maximum absorbance at about 226 nm of
the ﬁltered portions of the solution under test, suitably diluted
with dissolution medium, if necessary, in comparison with a
standard solution having a known concentration of potassiumiodide in the same medium. The results of the test were com-
pared to USP speciﬁcations of ‘‘not less than 75% (Q) of the
labeled amount of KI is dissolved in 15 min’’.
2.2.5. Tablet Breaking Force <USP 32: 1217>
This test is commonly known as ‘‘Hardness Test’’. It measures
the mechanical integrity of tablets and reports it as breaking
force values (i.e., the force required to cause tablets to break
in a speciﬁc plane). For conventional, round tablets, the load-
ing occurs across their diameter and fracture occurs in that
plane. Modern breaking force testers are usually calibrated
in kilopond or Newton units. The relationship between these
units of force is 1 kilopond = 1 kilogram-force (kgf) =
9.80 N. In this study, ten tablets were randomly selected. Each
tablet was placed between the two platens of the apparatus and
one platen was moved to apply sufﬁcient force to the tablet to
fracture. The reading, for each tablet in kilopond, was noted
down from the display of the apparatus.
2.2.6. Assay <USP 32 monograph>
The USP method was adopted with some modiﬁcations.
Brieﬂy, not less than 20 tablets were weighed and ﬁnely pow-
dered using a porcelain mortar and pestle. A portion of the
powder, equivalent to about 1.2 g of potassium iodide, was
transferred to a 250 mL volumetric ﬂask. To the ﬂask
100 mL of water was added, shaken for 20 min, diluted with
water to volume and mixed. A few milliliters of the solution
were ﬁltered using 0.2 lm syringe ﬁlter. The amount of KI
was determined from UV absorbance at the wavelength of
maximum absorbance at about 226 nm of the ﬁltered portions
of the solutions under test, suitably diluted with water, if nec-
essary, in comparison with a standard solution having a
known concentration of potassium iodide in the same medium.
The USP speciﬁcations for this test were met if Potassium
Iodide Tablets contained ‘‘not less than 94.0% and not more
than 106.0% of the labeled amount of KI for tablets of
300 mg or more’’.
2.2.7. Disintegration test <USP 32: 701>
One dosage unit was placed in each of the six tubes of the bas-
ket and a disk was added. The apparatus was operated using
98 A. Al-Achi, B. PatelDI water as the immersion ﬂuid, maintained at 37 ± 2 C. The
tablets were observed and the time was noted when all of the
tablets disintegrated completely. If 1 or 2 tablets failed to dis-
integrate completely, the test was repeated on 12 additional
tablets. The requirement was met if ‘‘not less than 16 of the
total of 18 tablets tested disintegrated’’.
2.2.8. Angle of repose <USP 32: 1174> test
The angle of repose is a measure of inter-particulate friction or
resistance to movement existing between particles of a powder.
The procedure included a ﬁxed base free of vibration. The fun-
nel height was maintained at 2.5 cm from the top of the pow-
der pile in order to minimize the impact of falling powder on
the tip of the cone. A symmetrical cone of powder was allowed
to build up by allowing the powder to ﬂow through the funnel.
The angle of repose was determined by measuring the diameter
of the cone of powder and calculating the angle of repose, a,
from the following equation:
tanðaÞ ¼ height=ð0:5  baseÞ2.2.9. Weight variation test <USP 20>
Twenty tablets were weighed individually and the average
weight was calculated. The individual tablet weights were then
compared to the average weight by calculating% difference as
per the formula stated below.Table 3 DoE results from the 15-run mixture design.
Run # Dissolution*
[n= 6]
Hardness*
(kP) [n= 10]
Assay
[n= 20]
1 116.20 ± 3.79 mg 6.27 ± 0.26 122.18 mg
89.39 ± 2.91% 93.98%
2 122.57 ± 1.76 mg 9.47 ± 0.51 120.60 mg
94.28 ± 1.35% 92.77%
3 116.68 ± 4.52 mg 4.93 ± 0.19 117.33 mg
89.75 ± 3.48% 90.25%
4 113.55 ± 5.30 mg 8.57 ± 0.53 123.29 mg
87.35 ± 4.08% 94.84%
5 106.30 ± 3.55 mg 5.02 ± 0.30 119.70 mg
81.77 ± 2.73% 92.08%
6 103.08 ± 2.58 mg 4.42 ± 0.39 121.02 mg
79.29 ± 1.99% 93.09%
7 108.99 ± 6.32 mg 5.59 ± 0.25 116.41 mg
83.84 ± 4.86% 89.55%
8 101.44 ± 1.96 mg 5.19 ± 0.19 130.85 mg
78.03 ± 1.51% 100.65%
9 108.68 ± 6.64 mg 5.60 ± 0.35 112.65 mg
83.60 ± 5.11% 86.65%
10 100.76 ± 2.72 mg 4.60 ± 0.20 115.43 mg
77.51 ± 2.09% 88.79%
11 106.93 ± 3.82 mg 10.05 ± 0.48 128.86 mg
82.26 ± 2.93% 99.12%
12 118.10 ± 4.19 mg 4.10 ± 0.13 149.81 mg
90.85 ± 3.22% 115.24%
13 114.62 ± 7.02 mg 10.49 ± 0.51 139.71 mg
88.17 ± 5.40% 107.47%
14 103.29 ± 3.64 mg 4.33 ± 0.20 147.82 mg
79.45 ± 2.80% 113.71%
15 118.77 ± 5.97 mg 4.27 ± 0.18 150.84 mg
91.36 ± 4.59% 116.03%
* Average ± SD; n = number of tablets used for the test.% difference ¼ ½ðweight averageÞ=average  100
The USP speciﬁcations were ‘‘not more than two of the tab-
lets must differ from the average weight by more than 5% as
stated in Table 3. No tablet must differ by more than 10%’’.
2.2.10. Scale-up and tests
The following units were used for scaling-up the tableting pro-
cedure: A balance (Ohaus Corporation, Model No. PA153); a
bench-top single punch tablet press (Shanghai Medical
Machinery Company, Model No. TDP 1.5Kn); a rotary mini
tablet press (Rimek Industries); a V-blender (Shanghai Medi-
cal Machinery Company, Model No. DH48S-2Z); and a coffee
grinder (Mr. Coffee, Model No. A117ME). Potassium iodide
was pulverized in a porcelain mortar for 3 min to prepare a
ﬁne powder. Stearic acid was ground for 1 min using coffee
grinder by setting to medium ﬁneness. All the ingredients
except magnesium stearate and stearic acid were added to
the V-blender. Then the V-blender was run for 20 min at a
speed of 18 rpm. After 20 min, magnesium stearate and stearic
acid were added to the V-blender. The blender was run for 5
more minutes to get a homogenous powder blend. For manu-
facturing the tablets, two batches each consisting of 1000 tab-
lets were prepared using two different tablet machines. Batch 1
was prepared on a bench-top single punch tablet press and
batch 2 was made by using a Rimek rotary mini tablet press.
The Rimek press had a total of 10 stations for punch and diesWeight variation*
(mg) [n= 20]
Disintegration
[n= 6]
Angle of
repose* ()
450.10 ± 1.80 3 min 2 s 34.29 ± 0.42
3.03 min Good
449.60 ± 2.28 20 s 32.77 ± 0.20
0.33 min Good
449.85 ± 2.25 3 min 27 s 35.93 ± 0.40
3.45 min Fair
450.05 ± 2.19 20 s 33.34 ± 0.35
0.33 min Good
448.60 ± 2.68 16 s 34.17 ± 0.21
0.27 min Good
449.70 ± 1.49 2 min 27 s 37.03 ± 1.04
2.45 min Fair
450 ± 1.92 32 s 36.20 ± 0.23
0.53 min Fair
449.60 ± 2.44 18 s 35.41 ± 0.23
0.30 min Good
449.75 ± 1.37 2 min 23 s 38.15 ± 0.25
2.38 min Fair
451.05 ± 1.54 3 min 18 s 37.29 ± 0.24
3.30 min Fair
450.45 ± 2.31 31 s 34.41 ± 0.37
0.52 min Good
451.05 ± 2.42 1 min 41 s 37.86 ± 0.50
1.68 min Fair
450.25 ± 2.24 23 s 33.35 ± 0.61
0.38 min Good
448.75 ± 2.00 2 min 44 s 37.01 ± 0.24
2.73 min Fair
450.60 ± 2.52 3 min 50 s 36.87 ± 0.24
3.83 min Fair
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The speed of the press was set so as to get an output of 22 tab-
lets per revolution. The following tests were conducted on the
manufactured tablets: Weight Variation Test according to
<USP 20>; Weight Variation Test according to <USP
32:905 >; Assay <USP 32: Monograph>(Modiﬁed method);
U.V. Visible spectrophotometer (JASCO Industries Ltd.,
Model # V530); Disintegration Test <USP 32: 701> using
a disintegration tester apparatus (VanKel Industries, Model
#35-1000); Dissolution Test <USP 32: 711> using dissolution
apparatus Type II (VanKel Industries, Model # v600); Tablet
breaking force test <USP 32: 1217 > using a hardness tester
(VanKel Industries, Model # 40-2000); and Photo-stability test
using light meter (VWR Industries, Model No. 62344-944)Figure 1 Prediction proﬁler for the results an
Table 4 Formula showing the amount of ingredients to be used fo
Ingredients Quantity (% w/w)
Potassium iodide 28.89
Microcrystalline cellulose (Avicel) 48.70
Silicon dioxide 0.27
Stearic acid 1.00
Magnesium stearate 2.45
Dicalcium phosphate 18.69
Total 100.00%(http://www.fda.gov/downloads/RegulatoryInformation/
Guidances/UCM129106.pdf).
The photo-stability testing involves exposure of dosage
form to ﬂuorescent light using artiﬁcial cool white ﬂuorescent
lamps. Initially, the intensity of light was measured using light
meter. According to ICH guidelines, time for which the tablets
must be exposed to light was obtained using the following
formula:
Time in hours ¼ ð1:2 106lux hoursÞ=intensity of light in lux
The tablets were chosen randomly and placed in a petri dish
to be exposed to ﬂuorescent light. Control Tablets (that were
not scheduled to be exposed to light) were placed in a petri dishalyzed by standard least squares method.
r the formulation obtained from the prediction proﬁler (Fig. 1).
Quantity for 1 tablet (mg) Quantity for 1000 tablets (g)
130.00 130.00
219.15 219.15
1.21 1.21
4.50 4.50
11.03 11.03
84.11 84.11
450.00 mg 450.00 g
Table 5 Summary of results for scale-up batches.
Tests Number of tablets used
for the test (n)
Result
Batch 1 Batch 2
Weight variation test
<USP 20>
20 441.35 ± 16.55 mg (Average ± S.D.)
Fails the test
451.1 ± 3.08 mg (Average ± S.D.)
Passes the test
Tablet breaking force test 10 1.55 ± 0.28 kP (Average ± S.D.) 6.73 ± 0.24 kP (Average ± S.D.)
Disintegration test 6 11 s 1 min 3 s
Assay 20 103.43%
134.46 mg
99.79%
129.72 mg
Dissolution test 6 103.81 ± 3.01%
134.95 ± 3.91 mg (Average ± S.D.)
94. 33 ± 3.96
122.63 ± 5.15 mg (Average ± S.D.)
Weight variation test
<USP 32>
30 chosen randomly out
of which 10 weighed
Acceptance value = 11.35
Passes the test
Acceptance value = 2.36
Passes the test
Table 6 Photosensitivity assay: Percentage of drug content
(average ± SD) of UV light exposed and unexposed tablets for
each day.
Day % Drug Content Exposed
Tablets [n= 3/day]
% Drug Content Unexposed
Tablets [n= 3/day]
0* 97.86 100.18
1 96.85 101.84
98.14 107.65
95.96 98.76
2 99.49 98.79
91.24 103.90
93.57 101.48
3 86.58 101.56
88.03 101.32
89.23 99.52
4 82.06 100.91
82.72 101.44
83.65 99.00
7 85.02 98.69
77.98 99.33
78.09 99.28
8 76.73 97.44
80.33 97.51
77.93 98.00
9 77.66 95.94
76.99 98.31
78.96 95.42
10 75.19 99.37
77.50 101.44
76.70 102.26
11 80.62 99.82
75.17 96.72
77.41 98.75
14 77.62 99.86
78.00 100.59
80.91 98.06
n= number of tablets tested.
* On day 0, only 1 tablet from each petri dish was analyzed.
100 A. Al-Achi, B. Pateland covered with an aluminum foil. Test tablets were placed in
an open petri dish. Both the petri dishes were then placed
under light. Sample from each petri dish was collected daily
and analyzed using UV Visible Spectrophotometry. Tablet
was taken, ground and transferred to 100 mL volumetric ﬂask.
First the powder was dissolved in 50 mL water and then the
volume was adjusted to 100 mL with water. A portion of the
solution was ﬁltered using 0.22 lm syringe ﬁlter. The amount
of KI dissolved was determined from UV absorbance at the
wavelength of maximum absorbance at about 226 nm of the
ﬁltered portions of the solutions under test, suitably diluted
with water, if necessary, in comparison with a standard solu-
tion having a known concentration of potassium iodide in
the same medium.
3. Results and discussion
The DoE results are summarized in Table 3. A prediction pro-
ﬁler in the DoE facility in JMP (Fig. 1) showed the concen-
tration of components that met the stated characteristics in
Table 2 (section 2.A.). According to the USP speciﬁcations
the ﬂow properties of the powder blend is ‘‘good’’ if the angle
of repose is between 31 and 35. Values between 25 and 30
indicate excellent ﬂow characteristics and values of 36 or
above indicate fair to poor ﬂow properties. Accordingly, a for-
mulation was adopted for scaling-up studies (Table 4). The
amount of dicalcium phosphate (18.69%) in the formulation
was determined from the difference between 100% and the
sum of total percent of the other ingredients in the
formulation.
Table 5 summarizes the results obtained from the tests con-
ducted on batch 1 and batch 2 of the scaled-up formulation.
While batch 2 passed the weight variation test, batch 1 did
not meet the requirements for the test outlined in USP 20
(more than 2 tablets exceeded the ofﬁcial limit of 5% for the
± percent difference from the mean). However, both batches
met the requirement for weight variation test according to
USP 32. Tablets made on the Rimek rotary mini tablet press
were harder than those prepared by the single-punch tablet
press. The disintegration time for the tablets correlated well
with their hardness (the greater the hardness of the tablet the
longer was the time needed to achieve disintegration.) Both
batches demonstrated similar proﬁles for their dissolution rate
test. According to USP 32 and as speciﬁed in the monograph
of Potassium Iodide Tablets ‘‘Potassium Iodide Tablets con-
tain not less than 94.0 percent and not more than 106.0 percentof the labeled amount of KI for tablets of 300 mg or more’’.
Both batches met this requirement based on the results
obtained from assay test.
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The data ﬁt well to a ﬁrst-order degradation kinetics proﬁle. The
estimated room temperature shelf-life (t94) of the product under
UV light exposure was estimated to be 3.4 days, and when pro-
tected from lightwas 25 days. The linear predictive equations for
the degradation of KI by UV light and without exposure to UV
light are estimated from equations (1) and (2), respectively:
ln ½% ContentðExposedÞ ¼ 4:54 0:018 Days ð1Þ
ln ½ð% ContentðUnexposedÞ ¼ 4:62 0:0025 Days ð2Þ
In summary, tablets containing potassium iodide (130 mg
of KI) prepared by the Rimek rotary mini tablet press demon-
strated good pharmaceutical characteristics and were stable at
room temperature for 25 days when protected from light.
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